# A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

> **NCT07415031** · PHASE2 · RECRUITING · sponsor: **Mirati Therapeutics Inc.** · enrollment: 170 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Adagrasib
- **DRUG:** Pembrolizumab
- **DRUG:** Cetuximab
- **DRUG:** Pemetrexed
- **DRUG:** Docetaxel
- **DRUG:** Irinotecan
- **DRUG:** Leucovorin
- **DRUG:** Oxaliplatin
- **DRUG:** Fluorouracil

## Key facts

- **NCT ID:** NCT07415031
- **Lead sponsor:** Mirati Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-06
- **Primary completion:** 2028-02-16
- **Final completion:** 2028-02-16
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07415031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07415031, "A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT07415031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*